This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.
A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Multiple Sclerosis, Acute Relapsing
You can join if…
Open to people ages 18 years to 70 years
Males or females (18-70 years of age; < 104 kg)
Capable of giving informed consent
Meet diagnostic criteria for MS, as defined by revised (2010) McDonald criteria
Present with a clinical acute relapse defined as a new or worsening neurological symptoms attributable to MS preceded by a stable or improving neurological state of at least 30 days, not associated with fever or infection, lasting at least 24 hours and accompanied by an objective physical (neurological) exam finding as confirmed by the Investigator
Has at least one new, identifiable, measurable and active lesion on MRI (Gd+) meeting the criteria of the imaging charter.
You CAN'T join if...
Certain specified co-morbidities (including pregnancy)
Taking certain proscribed medications
A medical regimen that has changed in the month prior to screening
Inability to undergo requisite MRI evaluations
Drug or alcohol abuse
Any other reason for which, in the opinion of the Investigator, the subject should not participate in the study.
Acorda Site #3accepting new patients Sacramento, California, 95817, USA
Acorda Site #7accepting new patients San Francisco, California, 94158, USA
Acorda Site #15withdrawn Stanford, California, 94305, USA
Acorda Site #12accepting new patients Long Beach, California, 90806, USA